Dynavax Technologies Corporation (DVAX) P/E Ratio History
ExpensiveTrading at 77.5x vs 5Y avg 48.0x · 79th percentile · Material premium to history · Data 2009–2024
Loading P/E history...
P/E Ratio Analysis
As of June 22, 2026, Dynavax Technologies Corporation (DVAX) trades at a price-to-earnings ratio of 77.5x, with a stock price of $15.50 and trailing twelve-month earnings per share of $-0.32.
The current P/E is 62% above its 5-year average of 48.0x. Over the past five years, DVAX's P/E has ranged from a low of 5.0x to a high of 229.8x, placing the current valuation at the 79th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, DVAX trades at a 250% premium to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.
Relative to the broader market, DVAX commands a significant premium over the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our DVAX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
DVAX Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
DVAX P/E vs Peers
Vaccines and biodefense products peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 3.6Lowest | - | +307% | |
| $310M | 13.1 | - | -60% | |
| $133M | 7.9 | - | +150% | |
| $143B | 18.5 | - | -4% | |
| $281B | 15.6 | 0.74 | +8% | |
| $102B | 6.9 | 0.49Best | +348%Best | |
| $102B | 18.2 | - | -7% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
DVAX Historical P/E Data (2009–2024)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2024 Q4 | - | $12.77 | $0.17 | 74.6x | +56% |
| FY2024 Q3 | Sep 30 2024 | $11.14 | $0.13 | 88.0x | +84% |
| FY2024 Q2 | Jun 30 2024 | $11.23 | $0.11 | 102.7x | +114% |
| FY2024 Q1 | Mar 31 2024 | $12.41 | $0.05 | 229.8x | +379% |
| FY2023 Q3 | Sep 30 2023 | $14.77 | $0.38 | 38.9x | -19% |
| FY2023 Q2 | Jun 30 2023 | $12.92 | $0.72 | 18.0x | -62% |
| FY2023 Q1 | Mar 31 2023 | $9.81 | $1.56 | 6.3x | -87% |
| FY2022 Q4 | Dec 31 2022 | $10.64 | $1.97 | 5.4x | -89% |
| FY2022 Q3 | Sep 30 2022 | $10.44 | $2.07 | 5.0x | -89% |
| FY2022 Q2 | - | $12.59 | $1.40 | 9.0x | -81% |
| FY2022 Q1 | - | $10.84 | $0.55 | 19.7x | -59% |
| FY2021 Q4 | Dec 31 2021 | $14.07 | $0.34 | 41.4x | -14% |
| FY2009 Q3 | Sep 30 2009 | $18.20 | $0.73 | 24.9x | -48% |
| FY2009 Q2 | - | $12.90 | $1.74 | 7.4x | -85% |
Average P/E for displayed period: 48.0x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
17+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
DVAX — Frequently Asked Questions
Quick answers to the most common questions about buying DVAX stock.
What is DVAX's P/E ratio?
Dynavax Technologies Corporation (DVAX) trailing twelve-month P/E ratio is 77.5x, based on TTM diluted EPS of $-0.32. The 5-year average P/E is 48.0x and the historical range spans 5.0x to 229.8x.
Is DVAX stock overvalued or undervalued?
DVAX trades at 77.5x P/E, above its 5-year average of 48.0x. The 79th percentile ranking within the 5.0x–229.8x historical range indicates a premium to historical valuation.
Is DVAX stock expensive?
Yes, DVAX is expensive relative to its own history. The current P/E of 77.5x is above the 5-year average of 48.0x and also above the Healthcare sector median of 22.1x. The stock sits at the 79th percentile of its 5-year valuation range.
What is DVAX's historical P/E range?
Over the past 5 years, DVAX's P/E ratio has ranged from 5.0x to 229.8x, with a median of 24.9x and an average of 48.0x. The current P/E of 77.5x places the stock at the 79th percentile of this range. Full historical data spans 2009–2024.
How does DVAX's P/E compare to the S&P 500?
DVAX trades at 77.5x P/E versus the S&P 500 median of 24.4x. The 218% premium to the market typically reflects higher expected earnings growth or quality.
How does DVAX's valuation compare to Healthcare peers?
Dynavax Technologies Corporation P/E of 77.5x compares to the Healthcare sector median of 22.1x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is DVAX's PEG ratio?
DVAX PEG ratio is N/A, based on a P/E of 77.5x and EPS growth of 503.2%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is DVAX's earnings yield?
DVAX earnings yield is 1.29%, the inverse of its 77.5x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.